Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SCNN1A
REST API REST API
Homo sapiens
SCNN1A is differentially expressed in 284 experiments: 183 organism parts: kidney, lung, ... (181 more);, 242 disease states: normal, prostate carcinoma, ... (240 more);, 99 cell types 553 cell lines 39 compound treatments and 81 other conditions.
Synonyms ENaCalpha, SCNN1
Orthologs Scnn1a (Mus musculus)   F1NWL3_CHICK (Gallus gallus)   SCNN1A (Bos taurus)   Scnn1a (Rattus norvegicus)   scnn1a (Xenopus laevis)   Q9GKK7_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cortical actin cytoskeleton, WW domain binding, plasma membrane, protein binding, sensory perception of taste, ion transport, membrane, ion channel activity, membrane fraction, external side of plasma membrane, response to stimulus, sodium ion transport, sodium channel activity, apical plasma membrane, integral to membrane, actin binding, sodium channel complex, excretion, ligand-gated sodium channel activity, sodium ion transmembrane transport
InterPro Term Na+channel_ASC, EnaC
UniProt Accession C5HTZ1, Q6UP09, B4E2Q5, P37088, F5GXE6, E7EVF3, F5H5F8
Gene-Disease Assocation PSEUDOHYPOALDOSTERONISM, TYPE I, AUTOSOMAL RECESSIVE; PHA1B, BRONCHIECTASIS WITH OR WITHOUT ELEVATED SWEAT CHLORIDE 2; BESC2
Search EB-eye ENSG00000111319
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-19397, ... (39 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-3529, E-GEOD-20081, E-GEOD-19639, E-GEOD-5823
BT474
3
E-MTAB-62, E-MTAB-37, E-MEXP-440
A549
2
E-GEOD-3202, E-GEOD-6013
BT-474
2
E-GEOD-3529, E-GEOD-5823
MOLT4
2
E-MTAB-37, E-MTAB-62
SKBR3
2
E-MEXP-440, E-MTAB-62
547 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-MEXP-120, ... (44 experiments)

Factor Value U/D Experiments
human embryonic stem cell
3
E-GEOD-18147, E-GEOD-20033, E-GEOD-18265
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
memory B cell
2
E-TABM-702, E-MEXP-2360
embryonic stem cell
2
E-MEXP-930, E-GEOD-2248
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
leydig cell
1
E-MTAB-25
93 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-TABM-15, E-GEOD-12254, E-GEOD-16363, ... (58 experiments)

Factor Value U/D Experiments
colorectal adenocarcinoma
3
E-AFMX-5, E-MTAB-62, E-TABM-145
gastric carcinoma
2
E-MTAB-37, E-GEOD-2685
acute quadriplegic myopathy
2
E-GEOD-3307, E-MTAB-62
ischemic cardiomyopathy
2
E-GEOD-1145, E-MTAB-62
benign prostatic hyperplasia
2
E-MEXP-2034, E-GEOD-7307
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
236 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-6907, E-GEOD-5741, E-GEOD-5824, E-TABM-868, ... (23 experiments)

Factor Value U/D Experiments
none
2
7
E-GEOD-5824, E-GEOD-3306, E-GEOD-3040, E-GEOD-412, E-GEOD-4668, ... (9 experiments)
NaOH
1
E-MEXP-2590
TGF-Beta1
1
E-MEXP-2645
interleukin-20 (Homo sapiens)
1
E-GEOD-7216
lipopolysaccharide
1
E-TABM-868
control - untreated
1
E-GEOD-7216
33 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
38 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125, E-GEOD-1729

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-MEXP-1828, E-GEOD-19743, E-MTAB-37, E-TABM-176, E-GEOD-6710, ... (12 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-GEOD-6236, E-GEOD-4667, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Er ihc
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-4922, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, ... (6 experiments)

Genotype
studied in E-GEOD-22056, E-MEXP-1437, E-GEOD-3494, E-GEOD-17476, E-GEOD-21750, ... (10 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-7011, E-MEXP-1446, E-GEOD-10315, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-974, E-MEXP-2069, E-TABM-15, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Nutrients
studied in E-MEXP-1243

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-1309, E-GEOD-21750, E-GEOD-2487

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

pt
studied in E-GEOD-21653

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22152, E-GEOD-16837, E-GEOD-19246, E-GEOD-13818

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4271, E-GEOD-3494, E-TABM-43, E-GEOD-1561, E-GEOD-6532, ... (7 experiments)

Tumor size
studied in E-GEOD-6532

Vehicle
studied in E-GEOD-5258

Processing time: 0.366 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM